Spyre Therapeutics, Inc. (SYRE) Tops Q1 EPS by 24c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.60), $0.24 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• MSCI upgrades Bulgaria to Frontier, flags Indonesia and Turkey risks
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT